Loading organizations...
§ Private Profile · Bridgewater, NJ, USA
Biotechnology company developing radiopharmaceuticals for disease diagnosis and treatments, focused on oncology and unmet needs.
Juniper Biosciences, based in Bridgewater, NJ, US, develops innovative radiopharmaceuticals using advanced radioisotopes linked to high-specificity ligands for earlier disease diagnosis and more effective treatments with minimized side effects, primarily addressing unmet needs in oncology. The seed-stage biotech firm secured an oversubscribed $40 million in seed funding in December 2025 to advance its preclinical studies and product development. This significant funding round was co-led by NovaCapital and Club Degli Investitori. Alex Agnoletto, formerly CFO at Evergreen Theragnostics, serves as CEO, while Indranil Nandi, PhD, holds the position of COO and is a co-founder. The company targets market expansion into Europe and Asia by 2026 with new oncology products. Juniper Biosciences was founded in 2025, with Indranil Nandi, PhD, listed among its founders.
Juniper Biosciences has raised $40.0M across 1 funding round.
Juniper Biosciences has raised $40.0M in total across 1 funding round.
Juniper Biosciences has raised $40.0M in total across 1 funding round.
Juniper Biosciences's investors include Club degli Investitori, NovaCapital.
Juniper Biosciences has raised $40.0M across 1 funding round. Most recently, it raised $40.0M Seed in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2025 | $40M Seed | Club Degli Investitori, NovaCapital | — | Announced |